Mikobeaute International (6574) reported revenue of NT$87.7 million for Oct 2026, +57.7% year on year and +23.4% from the previous month. Revenue for Jan–Oct 2026 was NT$713.3 million (+45.1% year on year).
Revenue for Oct 2026 was a record high (previous high: Jun 2026, NT$76.7 million). →
Year-on-year revenue growth: 11 months in a row. →
In Oct 2026, it ranked No. 82 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$87.7 million | +57.7% | +23.4% |
| Sep 2026 | NT$71.1 million | +81.3% | -0.5% |
| Aug 2026 | NT$71.4 million | +82.8% | +4.4% |
| Jul 2026 | NT$68.4 million | +23.7% | -10.8% |
| Jun 2026 | NT$76.7 million | +73.9% | +10.2% |
| May 2026 | NT$69.6 million | +39.4% | -4.5% |
| Apr 2026 | NT$72.9 million | +27.1% | +7.8% |
| Mar 2026 | NT$67.6 million | +6.8% | +10.0% |
| Feb 2026 | NT$61.4 million | +39.8% | -7.5% |
| Jan 2026 | NT$66.4 million | +52.2% | -4.0% |
| Dec 2025 | NT$69.2 million | +26.2% | +13.5% |
| Nov 2025 | NT$61 million | -4.0% | +9.7% |
| Oct 2025 | NT$55.6 million | +4.4% | +41.8% |
| Sep 2025 | NT$39.2 million | -20.7% | +0.3% |
| Aug 2025 | NT$39.1 million | -16.8% | -29.4% |
| Jul 2025 | NT$55.3 million | +36.4% | +25.5% |
| Jun 2025 | NT$44.1 million | +9.4% | -11.7% |
| May 2025 | NT$49.9 million | -2.3% | -12.9% |
| Apr 2025 | NT$57.3 million | -3.1% | -9.4% |
| Mar 2025 | NT$63.3 million | +39.9% | +44.0% |
| Feb 2025 | NT$44 million | +16.6% | +0.7% |
| Jan 2025 | NT$43.7 million | +5.1% | -20.4% |
| Dec 2024 | NT$54.8 million | -12.3% | -13.7% |
| Nov 2024 | NT$63.5 million | +15.7% | +19.2% |
| Oct 2024 | NT$53.3 million | -12.3% | +7.8% |
Jan–Oct 2026 cumulative: NT$713.3 million (+45.1% YoY)
Other Biotech & Medical companies
Compare with peers: Mikobeaute International vs PEC / Mikobeaute International vs Lotus Pharm / Mikobeaute International vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本月較去年同期增加57.74%,主係美學健康通路業務持續成長,帶動相關服務及醫材銷售增加。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16